Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA PortfolioJune 06, 2025 7:45 AM EDT | Source: Phio Pharmaceuticals Corp.- Robert Infarinato named VP, Strategic Development- Lisa Carson named as new VP, Finance and AdministrationMarlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® g ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36304 Phio Pharmaceuticals Corp. (Exact name of registrant as specified in its charter) Delaware 45-3215903 (State or ot ...

Exhibit 99.1 Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical study Marlborough, Massachusetts-(Newsfile Corp.-May 15, 2025) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune ce ...

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 4:15 PM EDT | Source: Phio Pharmaceuticals Corp.Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - May 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therapeutics that use its INTASYL® siRNA ...

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical TrialMay 07, 2025 7:45 AM EDT | Source: Phio Pharmaceuticals Corp.Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual Meeting on May 10thMarlborough, Massachusetts--(News ...

Here are two stocks with buy rank and strong value characteristics for investors to consider today, April 23:Phio Pharmaceuticals Corp. (PHIO) : This immuno-oncology biotech company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing by 14.4% over the last 60 days.Phio Pharmaceuticals has a price-to-earnings ratio (P/E) of 0.66 compared with 7.20 for the industry. The company possesses a Value Scoreof B.Transportadora de Gas del Sur S.A. (TGS) : T ...

Core Viewpoint - Phio Pharmaceuticals has received a positive recommendation from the Safety Monitoring Committee to advance its Phase 1b clinical trial of PH-762, a siRNA compound targeting skin cancer, to the fourth dose escalation cohort, indicating a supportive safety profile in the previous cohort [1][2]. Group 1: Clinical Trial Details - The Phase 1b clinical trial is a multi-center, dose-escalating study aimed at evaluating the safety and tolerability of intratumoral PH-762 in patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma [2][6]. - In the third cohort, three patients with cutaneous squamous cell carcinoma were enrolled, and the injections were well tolerated with no serious adverse events or dose-limiting toxicities reported [2][4]. - Previous cohorts included seven patients, with the second cohort showing two patients achieving a complete response (100% tumor clearance) and one patient showing a partial response (90% clearance) [4]. Group 2: Company Insights - Phio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to combat cancer [1][6]. - The lead product candidate, PH-762, is designed to silence the PD-1 gene, which is implicated in various forms of skin cancer, and is being evaluated as a potential non-surgical treatment option [6][5]. - The company expresses optimism that PH-762 may provide a viable alternative to existing therapies for skin cancer [5].

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894April 03, 2025 7:45 AM EDT | Source: Phio Pharmaceuticals Corp.To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary INTASYL® gene silencing technology ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36304 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) (State or other jurisdictio ...

Exhibit 99.1 Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762 3 Cohort now fully enrolled in on-going clinical study Marlborough, Massachusetts-(Newsfile Corp.-March 31, 2025) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL siRNA gene silencing technology designed to make the body's immune cells more ef ...